Mycobacterium Infections  >>  SQ-109  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SQ-109 / Sequella
NCT01358162: Phase IC Study of Safety and PK of SQ109 300mg Daily

Completed
1c
10
US
Placebo, SQ109
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
02/11
04/11
NCT00866190: Dose Escalation Study of SQ109 in Healthy Adult Volunteers

Completed
1b
10
US
SQ109, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
TB Multi-drug Resistant
11/09
11/09
NCT01585636: Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers

Completed
1
62
US
SQ109
Sequella, Inc., Quintiles, Inc.
Tuberculosis
02/07
02/07
NCT01874314: Effects of SQ109 on QTc Interval in Healthy Subjects

Withdrawn
1
0
US
SQ109, SQ109 Placebo, Moxifloxacin
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
12/15
12/15

Download Options